DIBENZEPIN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C18H21N3O
Molecular Weight	295.3788
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)CCN1C2=C(C=CC=C2)N(C)C3=C(C=CC=C3)C1=O

InChI

InChIKey=QPGGEKPRGVJKQB-UHFFFAOYSA-N

InChI=1S/C18H21N3O/c1-19(2)12-13-21-17-11-7-6-10-16(17)20(3)15-9-5-4-8-14(15)18(21)22/h4-11H,12-13H2,1-3H3

HIDE SMILES / InChI

Description
Sources: Leigh, D., Pare, C.M., Marks, J. (2012) A Concise Encyclopaedia of Psychiatry, page 380, retrieved from: https://books.google.ru/books?id=o-bzCAAAQBAJ
Curator's Comment: Description was created based on several sources, including http://mentalhealthdaily.com/2014/08/18/tricyclic-antidepressants-list-tcas/

Dibenzepin is a tricyclic antidepressant of the dibenzo-epine group. It is a selective noradrenaline uptake inhibitor, which exhibits in vitro and in vivo imipramine-like effects. It binds strongly to histamine H1 receptors in the brain and, to a lesser extent, to cholinergic receptors. The pharmacological profile of dibenzepin corresponds widely to its biochemical properties: histamine antagonism, tetrabenazine antagonism, potentiation of various noradrenergic effects and anticholinergic effects. Dibenzepin is only available in European countries for the treatment of depression.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H1 receptor 315 Target ID: CHEMBL231 Sources: http://www.pharmawiki.ch/wiki/index.php?wiki=Dibenzepin	Antagonist 2778
Monoamine transporter 10 Target ID: CHEMBL2363064 Sources: http://www.kegg.jp/entry/D07812	Inhibitor 8297
Muscarinic acetylcholine receptor 160 Target ID: CHEMBL2094109 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20647 \| https://www.old.health.gov.il/units/pharmacy/trufot/alonim/4401.pdf	Antagonist 2778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Depression 235 Sources: https://www.ncbi.nlm.nih.gov/pubmed/5492203	Primary		Approved 8429	NOVERIL Approved Use Noveril (dibenzepin) is indicated for the treatment of depression

PubMed

Title	Date	PubMed
Drug-induced rapid cycling: possible outcomes and management.	1982 Jul	6124134
Direct-injection high performance liquid chromatography ion trap mass spectrometry for the quantitative determination of olanzapine, clozapine and N-desmethylclozapine in human plasma.	2002	12112253
Simultaneous determination of seven tricyclic antidepressant drugs in human plasma by direct-injection HPLC-APCI-MS-MS with an ion trap detector.	2002 Aug	12142640
Discrimination in 5-HT(3) receptor binding in murine brain and cultured cell preparations.	2002 Feb	11819030
Comparison of trazodone, diazepame and dibenzepine influences on rat brain beta-endorphins content.	2007 Aug	17848146

Patents

Sample Use Guides

In Vivo Use Guide

In adult patients, treatment should begin with Noveril (dibenzepin) 240 mg tablets, the daily dose being given as a single dose or in 2 divided dose.

Route of Administration: Oral

In Vitro Use Guide

Dibenzepin blocked calcium current in enzymatically isolated rat ventricular myocytes with IC(50) values of 364 uM.

Name

Type

Language

DIBENZEPIN

Official Name

English

10-(2-(DIMETHYLAMINO)ETHYL)-5,10-DIHYDRO-5-METHYL-11-H-DIBENZO(B,E)(1,4)DIAZEPIN-11-ONE

Common Name

English

DIBENZEPINE

Common Name

English

Dibenzepin [WHO-DD]

Common Name

English

DIBENZEPIN [MI]

Common Name

English

dibenzepin [INN]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QN06AA08